The board of Suven Life Sciences approved raising upto Rs 400 crore by issuing equity shares on right basis.
The board has also approved increase in the authorized share capital from Rs 20 crore divided into 20 crore equity shares of Rs 1 each to Rs 30 crore divided into 30 crore equity shares of Rs 1 each and consequential alteration in the memorandum of association of the company, subject to the approval of shareholders of the company.Suven Life Science is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
On consolidated basis, the pharmaceutical company reported a net loss of Rs 20.80 crore as against a net loss of Rs 21.61 crore in Q4 FY22 over Q4 FY21. Net sales jumped 170.5% YoY to Rs 4.22 crore during the quarter.
Shares of Suven Life Sciences rose 0.59% to Rs 76.90 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app